Home Newsfeeds Needham Upgrades Tesla to Hold

Needham Upgrades Tesla to Hold

Needham analyst Vikram Bagri upgrades Tesla (NASDAQ:TSLA) from Underperform to Hold.

byBenzinga Newsdesk

September 15, 2022

1 minute read

Needham analyst Vikram Bagri upgrades Tesla (NASDAQ:TSLA) from Underperform to Hold.

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $85

By Benzinga Newsdesk

August 24, 6:21 AM

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $110 to $85.

BTAI

Heron Shares Jump After Equity Financing, Q2 Earnings

By Vandana Singh

August 9, 2:10 PM

Heron Therapeutics Inc (NASDAQ:HRTX) reported Q2 sales of $27.63 million, +23.1% Y/Y, beating the consensus of $24.31 million. Oncology sales…

HRTX

Inhibrx Announces Preliminary Data From The Phase 1 Trial Of Inbrx-109 For The Treatment Of Ewing Sarcoma

By Benzinga Newsdesk

November 2, 9:20 AM

Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1

INBX

UPLIZNA Approved In Brazil For The Treatment Of Neuromyelitis Optica Spectrum Disorder

By Benzinga Newsdesk

December 20, 9:07 AM

-- First and only anti-CD19 B-cell-depleting monotherapy for the treatment of adult patients with NMOSD who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+) -- -- NMOSD is a devastating rare

HZNP

Needham Upgrades Tesla to Hold

Related Posts

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $85

Heron Shares Jump After Equity Financing, Q2 Earnings

Inhibrx Announces Preliminary Data From The Phase 1 Trial Of Inbrx-109 For The Treatment Of Ewing Sarcoma

UPLIZNA Approved In Brazil For The Treatment Of Neuromyelitis Optica Spectrum Disorder